Asset Manager

Updated:

TerSera Therapeutics LLC

TerSera Therapeutics LLC, a Deerfield-based biopharmaceutical company chaired by Edward J.

TerSera Therapeutics LLC

Edward J. Fiorentino serves as Executive Chairman of TerSera Therapeutics LLC, a biopharmaceutical company headquartered in Deerfield, Illinois. The firm's founding year and wealth origin are not publicly disclosed. TerSera states it follows the science toward therapies with untapped potential and amplifies their ability to address unmet needs. The company leverages expertise to advance a portfolio described as one-and-only therapeutics, alongside comprehensive support services. No specific asset-class mix, stage coverage, fund-structure shape, or named portfolio companies, deals, or co-investors are confirmed in public sources. The company operates from a single disclosed office in Deerfield and its team size is not publicly known. No additional offices, adjacent vehicles (philanthropic foundations, real-asset arms, or clubs) have been identified. No dated operational event from the last 24 months has been confirmed. TerSera's structural differentiator is its sole disclosed principal and its deliberate opacity, with no public details on ownership, investment strategy, or financial scale — distinguishing it as a private entity that provides minimal information to external observers.

General information

Firm type

Asset Manager

Year founded

AUM

Undisclosed

Location

Region

North America

Country

United States

City

Deerfield

Corporate office

Deerfield, IL, United States

Principals

Edward J. Fiorentino

Executive Chairman

Sector focus

Biotech

Frequently asked questions

Who runs investment decisions at TerSera Therapeutics?

Edward J. Fiorentino serves as Executive Chairman, the only named principal disclosed on the firm's website. No other investment decision-makers are publicly identified.

Is TerSera Therapeutics structured as a single-family office, a venture firm, or something else?

TerSera Therapeutics operates as a biopharmaceutical company, not a traditional family office or venture firm. Its corporate structure and ownership are not publicly disclosed.

How does TerSera source proprietary deal flow?

The firm states it follows the science toward therapies with untapped potential but does not describe its deal-sourcing methods. No acquisitions, partnerships, or co-investments have been publicly confirmed.

What investment stages does TerSera typically target?

TerSera does not publicly disclose its investment stage targets. The company's product descriptions suggest a focus on late-stage therapies or marketed drugs, but no stage-specific information is available.

Which sectors does TerSera explicitly focus on?

TerSera operates exclusively in the biopharmaceutical sector. It does not disclose sectors it avoids, but its known activities are limited to therapeutic development and commercialization.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo